Mohammed Najeeb Al Hallak, M.D., MS

Specialties

Oncology - Medical

Board Certification

American Board of Internal Medicine, Medical Oncology and Hematology

Multidisciplinary Team

Language(s) Spoken

Arabic, English

Locations

Karmanos Cancer Center
4100 John R
Detroit, MI 48313
Get Directions

Phone:1-800-KARMANOS

Call For Appointment

Podcast: Listen

Cancers Treatments

Cancers Treated

Locations

Karmanos Cancer Center

4100 John R
Detroit, MI 48313
Get Directions

Phone:1-800-KARMANOS

Get Directions

Education

Cancers Treatments

Clinical Trials

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient D

Cancer Category
Gastrointestinal (GI)
Age Group
Adult
Phase
Phase III

Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)

Cancer Category
Gastrointestinal (GI)
Age Group
Adult
Phase
Phase II/III

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (EMERALD-Y90)

Cancer Category
Gastrointestinal (GI)
Age Group
Adult
Phase
Phase II

Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma

Cancer Category
Gastrointestinal (GI)
Age Group
Adult
Phase
Phase III

A Phase II, Open-Label, Multicohort, Multicenter Study in Patients with Unresectable Hepatocellular Carcinoma and Child-Pugh B Cirrhosis

Cancer Category
Gastrointestinal (GI)
Age Group
Adult
Phase
Phase II

An Open-Label Study of GV20-0251 in Patients with Advanced and/or Refractory Solid Tumor Malignancies

Cancer Category
Gastrointestinal (GI),Genitourinary (GU),Head and Neck,Lung,Skin
Age Group
Adult
Phase
Phase I

A Phase 1 Open-label, Dose-escalation and Cohort Expansion Study of LUNA18 Monotherapy and Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

Cancer Category
Gastrointestinal (GI),Lung
Age Group
Adult
Phase
Phase I

A Phase 1b/2 Multicenter, Open-label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants with Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Cancer Category
Gastrointestinal (GI)
Age Group
Adult
Phase
Phase I/II

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability and Clinical Activity of Decoy20 in Patients with Advanced Solid Tumors

Cancer Category
Gastrointestinal (GI),Gynecologic
Age Group
Adult
Phase
Phase I

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors

Cancer Category
Breast,Gastrointestinal (GI),Genitourinary (GU),Gynecologic,Lung
Age Group
Adult
Phase
Phase I

Additional Info

Dr. Al Hallak has a broad background in medicine, with specialized training in oncology. He has profound clinical expertise in managing Gastrointestinal (GI) malignancies, in particular, pancreatic cancer. Additionally, Dr. Al Hallak has a robust clinical research training provided by the University of Michigan Master of Science program in clinical research design and statistical analysis, as well as a solid basic science training at Karmanos Cancer Institute.

His research focus is in gastrointestinal malignancies, specifically pancreatic cancer. The goal of his research is to better understand the molecular biology and microenvironment of GI cancers, discover new treatments and prevent treatment-induced toxicities. He is able to translate passion for improving treatment outcomes for GI cancer patients via conducting clinical trials (phase I-III), investigator-initiated and pharma-sponsored. Dr. Hallak works through translational research to identify new biomarkers that help to individualize the treatment choice for patients and provide them with an accurate prediction of the treatment effect as well as a prognosis of their cancer. He is leading the initiative to start a postmortem rapid autopsy program for pancreatic cancer patients in Detroit. Additionally, he is a co-principal investigator on our Translational Pilot Trial to study the role of different microRNAs in predicting response and resistance to Gemcitabine and Nab-Paclitaxel when used as first-line therapy for metastatic or locally advanced unresectable Pancreatic cancer patients. He is also a co-leader for the Phase II Clinical Trial to study the effect of adding XPO1 inhibitor (Selinexor) to Gemcitabine as a second-line treatment for patients with metastatic or locally advanced unresectable pancreatic cancer patients after non-Gemcitabine regimen failure.

Related News

November 05, 2024
Karmanos Cancer Institute Recognizes Pancreatic Cancer Awareness Month, the Third Deadliest Cancer

The Barbara Ann Karmanos Cancer Institute , cancer centers, and other organizations nationwide recognize November as Pancreatic Cancer Awareness Month. As its name indicates, pancreatic cancer originates in the pancreas, an organ that sits behind the stomach. The pancreas aids in digestion and helps regulate blood sugar. About Pancreatic Cancer Exocrine cells make up much of the pancreas. When these cells grow out of control, adenocarcinoma of the pancreas occurs. Pancreatic adenocarcinomas account for ...
Read More
October 15, 2024
Karmanos Faculty Honored at Annual WSU School of Medicine Faculty Awards and Promotion and Tenure Ceremony

The Office of Faculty Affairs and Professional Development at Wayne State University’s (WSU) School of Medicine held its 2024 School of Medicine Faculty Awards and Promotion and Tenure Ceremony on Sept. 26. This is an annual recognition of faculty who have made outstanding contributions to teaching, mentoring, research, and leadership. This year, several Barbara Ann Karmanos Cancer Institute faculty, researchers and medical staff at the Karmanos Cancer Center received these awards, highlighting their si...
Read More
October 02, 2024
Hour Detroit’s 2024 Top Docs List Includes Over 50 Karmanos Physicians

Hour Detroit’s 2024 Top Docs List is out; over 50 physicians from the Barbara Ann Karmanos Cancer Institute are listed. Each year, Hour Detroit Magazine puts out an online peer-to-peer review survey conducted by Professional Research Services (PRS) to determine the top physicians in southeastern Michigan. Participating physicians in Livingston, Macomb, Oakland, Washtenaw, and Wayne Counties nominate the best doctors in each field. This year’s list also includes a feature with Elisabeth...
Read More

Awards

2024 Detroit's Top Doctors, Hour Magazine

2023 Wayne State University School of Medicine College Teaching Award

July 2019: June 2020: Chief Fellow, Hematology-Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI

November 2019: FDA-ASCO Hematology-Oncology Fellow Day Workshop Travel Grant

August 2016: Awesome Job Award; MD Anderson Cancer Center, Houston, TX

May 2013: Internal Medicine Faculty outstanding teacher of the year, University of North Dakota, Fargo, ND

May 2011: Excellence in Research Award. University of North Dakota, Fargo, ND

July 2010 – June 2011: Chief Resident, Internal Medicine & Transitional Year Program, University of North Dakota School of Medicine and Health Sciences, Fargo, ND.

Professional Memberships

American Society of Clinical Oncology (ASCO)
American Association for Cancer Research (AACR)

Publications

Preclinical assessment with clinical validation of Selinexor with gemcitabine and nab-paclitaxel for the treatment of pancreatic ductal adenocarcinoma. Azmi AS, Khan HY, Muqbil I, Aboukameel A, Neggers JE, Daelemans D, Mahipal A, Dyson G, Kamgar M, Al Hallak MN, Tesfaye A, Kim S, Shidham V, Ramzi M, Philip PA. Clinical Cancer Research. 2019: clincanres. 1728.2019. doi: 10.1158/1078-0432.CCR-19-1728.
Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth. Husain Yar Khan. Gabriel Mpilla, Rachel Sexton, Srikant Viswanadha, Kumar V. Penmetsa, Amro Aboukameel, Maria Diab, Mandana Kamgar, Mohammed Najeeb Al Hallak, Mark Szlaczky, Anteneh Tesfaye, Steve Kim, Philip A. Philip, Ramzi M. Mohammad and Asfar S. Azmi. Cancers. March 22, 2020, 12, 750; doi:10.3390/cancers12030750
Comprehensive genomic profiling in metastatic pancreatic adenocarcinoma, correlation with early death versus prolonged survival. Kamgar M., Dyson G., Shields AF., Tesfaye A., Philip PA., Al Hallak MN; DOI: 10.1200/JCO.2019.37.4_suppl.282 Journal of Clinical Oncology 37, no. 4_suppl. Published online January 29, 2019.
Gastric Cancer Heterogeneity and Clinical Outcomes. Rachel Sexton, Mohammed Al Hallak, Md. Uddin, Maria Diab, Asfar Azmi. Technology in Cancer Research & Treatment Journal. Accepted for publication on 06/08/2020. DOI: 10.1177/1533033820935477. KRAS G12C
Game of Thrones, which direct KRAS inhibitor will claim the iron throne? Nagasaka M, Li Y, Sukari A, Ou SI, Al-Hallak MN, Azmi AS. Cancer Treat Rev. 2020; 84:101974. doi:10.1016/j.ctrv.2020.101974

Provider Profile:
Mohammed Najeeb Al Hallak, M.D., MS